Public record
Rybelsus: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicaid
Medicaid prescriptions for Rybelsus by state
State Medicaid programmes paid for 200,179 Rybelsus prescriptions in 2025, with $256.7M reimbursed before rebates. California reported the most (85,505), followed by New York (24,252) and Illinois (23,662); 51 states and territories reported any.
| Measure | Value | Note |
|---|---|---|
| Prescriptions paid by Medicaid, 2025 | 200,179 | |
| Total reimbursed before rebates, 2025 | $256.7M | |
| States and territories reporting | 51 | with at least one count CMS did not suppress |
| California | 85,505 prescriptions | $123.4M reimbursed |
| New York | 24,252 prescriptions | $32.9M reimbursed |
| Illinois | 23,662 prescriptions | $28.7M reimbursed |
| Maryland | 7,465 prescriptions | $7.1M reimbursed |
| North Carolina | 4,309 prescriptions | $5.5M reimbursed |
How this was calculated
Matched each Medicaid product code to the FDA NDC Directory by labeler and product code, kept finished single-ingredient products, then summed prescriptions and reimbursement by state. National roll-up and suppressed rows dropped.
Rybelsus only (brand-name semaglutide), fee-for-service and managed care, 2025
Counts under 11 are suppressed by CMS and left out, so totals are a floor. Amounts are before rebates. Differences between states reflect programme size and coverage rules. Compounded products are not included.
Pharmacy cost
Pharmacy acquisition cost (NADAC) for Rybelsus
Retail pharmacies paid an average of $33.19 per unit for RYBELSUS 14 MG TABLET as of 2026-11-11, compared with $32.19 twelve months earlier (+3.1%). This is a pharmacy purchase cost, not a patient price.
| Measure | Value | Note |
|---|---|---|
| RYBELSUS 14 MG TABLET | $33.19 per unit | 12 months earlier $32.19 (+3.1%) |
| RYBELSUS 3 MG TABLET | $33.19 per unit | 12 months earlier $32.19 (+3.1%) |
| RYBELSUS 7 MG TABLET | $33.19 per unit | 12 months earlier $32.20 (+3.1%) |
How this was calculated
Matched NADAC product codes to the FDA NDC Directory, kept finished single-ingredient products, and listed the product descriptions with the most package codes. The earlier price is the same package code in the file one year before.
Rybelsus (brand-name semaglutide) in the weekly NADAC file of 2026-11-11, compared with the file of 2025-11-12
NADAC is the average invoice price retail pharmacies pay, from a voluntary survey. It leaves out rebates, dispensing fees and markups, and it is not what a patient or insurer pays. Compounded products are not surveyed.
Articles on Rybelsus
- Does Aetna (CVS Health) Cover Rybelsus? Prior Authorization, Formulary Tier, and Appeal Steps
- Does Anthem (Elevance Health) Cover Rybelsus?
- Does Blue Cross Blue Shield (Federated) Cover Rybelsus?
- Rybelsus Cost vs. Alternatives in Class: Oral Semaglutide Pricing, Efficacy, and Value Comparison
- Does Kaiser Permanente Cover Rybelsus? Formulary Status, Prior Authorization, and Appeal Options
- Does UnitedHealthcare Cover Rybelsus? Coverage, Prior Auth, and Appeals Explained